<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4672">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01658202</url>
  </required_header>
  <id_info>
    <org_study_id>V00116 TD 1 04</org_study_id>
    <secondary_id>2011-006212-32</secondary_id>
    <nct_id>NCT01658202</nct_id>
  </id_info>
  <brief_title>Nicotine Patch Bioequivalence Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Comité de Protection des Personnes</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the relative bioavailability of nicotine following
      single application of a new transdermal formulation to that of a reference formulation.

      4 single 24hour applications separated by 48hour intervals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Pharmacokinetic profile</measure>
    <time_frame>Blood samples will be collected on Days 1, 3, 5 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic profile of nicotine following a single patch application by measuring Maximum Plasma Concentration, Time of Maximum Concentration, Area under the nicotine plasma concentration curve,  for each test and reference formulations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical safety (reported adverse events)</measure>
    <time_frame>up to day 9</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>General and local safety by evaluating the number of subjects with emergent adverse events or changes from baseline to end of study in vital signs, electrocardiogram, haematology and biochemistry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy Smokers</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.
Each patch will be applied for 24h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.
Each patch will be applied for 24h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V0116 transdermal patch (Test treatment )</intervention_name>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine transdermal patch (Reference Treatment )</intervention_name>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subject aged 18 to 45 years (inclusive)

          -  Current Smoker of &gt;or = 5 and &lt; or = 15 cigarettes/day

          -  Fagerström score &lt; or =5 at selection

          -  Absence of any clinically significant abnormal finding at physical, vital sign,
             Electrocardiogram ECG, biological examinations in the investigator's opinion.

        Exclusion Criteria:

          -  Presence of any significant medical finding or significant history (in particular any
             cardio-vascular disease, severe renal or hepatic insufficiency, current gastric or
             duodenal ulcer) that may impact the safety, the interpretation of the results and/or
             the participation of the subject in the study according to the opinion of the
             investigator

          -  Any visible skin disorder, abnormal skin pigmentation or dermatologic disease liable
             to interfere with use or assessment of transdermal patch
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 10, 2012</lastchanged_date>
  <firstreceived_date>July 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking cessation</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Tobacco Use Disorder</keyword>
  <keyword>Central Nervous System Agents</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Central Nervous System Agents</mesh_term>
    <mesh_term>Nicotine polacrilex</mesh_term>
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
